RxDoctor Payments Data

Joanna Wahl, DO

Ophthalmology · South Miami, FLNPI 1558548586

Payments from drug & device makers

$3,988in general payments, 2019–2025

Across 123 payments — averaging $32.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$538
  • Johnson & Johnson Surgical Vision, Inc.$502
  • NEW World Medical,inc.$340
  • Biotissue Holdings Inc.$241
  • Novartis$232
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,89598%
  • Education$932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,988 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$45,209
Medicare patients
99
Services billed
638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine290$263,375
XiidraLifitegrast44$45,676
LumiganBimatoprost103$42,510
Cyclosporine33$12,604
BotoxOnabotulinumtoxina13$8,424
Prednisolone Acetate202$7,481
CombiganBrimonidine Tartrate/Timolol13$5,930
VyzultaLatanoprostene Bunod15$4,984
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha453$4,475
Alphagan PBrimonidine Tartrate17$4,470
LotemaxLoteprednol Etabonate11$3,930
ZioptanTafluprost/Pf11$2,756
Latanoprost234$2,610
Travoprost20$2,572
Brimonidine Tartrate25$2,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Botox, Combigan, Alphagan P$1,102$324,709436 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$175$50,65959 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in South Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →